- Home
- SLN vs ZURA Comparison
SLN vs ZURA Comparison
Compare SLN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLN
- ZURA
- Stock Information
- Founded
- SLN 1994
- ZURA 2022
- Country
- SLN United Kingdom
- ZURA United States
- Employees
- SLN N/A
- ZURA N/A
- Industry
- SLN Biotechnology: Pharmaceutical Preparations
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SLN Health Care
- ZURA Health Care
- Exchange
- SLN Nasdaq
- ZURA Nasdaq
- Market Cap
- SLN 352.2M
- ZURA 292.1M
- IPO Year
- SLN N/A
- ZURA N/A
- Fundamental
- Price
- SLN $5.12
- ZURA $1.77
- Analyst Decision
- SLN Strong Buy
- ZURA Buy
- Analyst Count
- SLN 4
- ZURA 6
- Target Price
- SLN $61.50
- ZURA $15.80
- AVG Volume (30 Days)
- SLN 460.0K
- ZURA 613.7K
- Earning Date
- SLN 03-11-2025
- ZURA 03-12-2025
- Dividend Yield
- SLN N/A
- ZURA N/A
- EPS Growth
- SLN N/A
- ZURA N/A
- EPS
- SLN N/A
- ZURA N/A
- Revenue
- SLN $21,773,221.00
- ZURA N/A
- Revenue This Year
- SLN N/A
- ZURA N/A
- Revenue Next Year
- SLN $104.98
- ZURA N/A
- P/E Ratio
- SLN N/A
- ZURA N/A
- Revenue Growth
- SLN N/A
- ZURA N/A
- 52 Week Low
- SLN $4.82
- ZURA $1.76
- 52 Week High
- SLN $27.72
- ZURA $6.35
- Technical
- Relative Strength Index (RSI)
- SLN 25.52
- ZURA 30.04
- Support Level
- SLN $4.82
- ZURA $1.86
- Resistance Level
- SLN $7.87
- ZURA $2.08
- Average True Range (ATR)
- SLN 0.62
- ZURA 0.21
- MACD
- SLN -0.01
- ZURA -0.03
- Stochastic Oscillator
- SLN 9.20
- ZURA 1.55
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
About ZURA Zura Bio Limited
Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.